Physician profile
Michael Marro
NPI 1639592983
$2,974.32
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.97 · 2020: $673 · 2021: $665 · 2022: $395 · 2023: $772 · 2024: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,169.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $381.62 | 2021-2024 | |
| Glaxosmithkline, LLC. | $366.33 | 2019-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $257.64 | 2020-2024 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $255.53 | 2019-2024 | Xarelto |
| Astellas Pharma US INC | $169.33 | 2019-2021 | |
| Lilly USA, LLC | $139.71 | 2020-2024 | Amyvid, Mounjaro |
| Pfizer INC. | $117.11 | 2022-2024 | |
| Novo Nordisk INC | $112.51 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $99.20 | 2024 | Intellis Adaptivestim |
| Exact Sciences Corporation | $98.19 | 2023 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $93.31 | 2020-2022 | |
| Daiichi Sankyo INC. | $92.86 | 2020-2024 | Injectafer |
| Collegium Pharmaceutical, INC. | $81.50 | 2023-2024 | Belbuca |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.42 | 2020-2023 | Jardiance |
| Sumitomo Pharma America, INC. | $59.13 | 2023 | Gemtesa |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Marro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.